Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis.

Guo X, Higgs BW, Rebelatto M, Zhu W, Greth W, Yao Y, Roskos LK, White WI.

Rheumatology (Oxford). 2014 Apr;53(4):686-95. doi: 10.1093/rheumatology/ket413. Epub 2013 Dec 19.

2.

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.

Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P, Guo X, Rebelatto M, Le C, Amato A, Fiorentino D, Greenberg SA, Drappa J, Richman L, Greth W, Jallal B, Yao Y.

Ann Rheum Dis. 2014 Jan;73(1):256-62. doi: 10.1136/annrheumdis-2012-202794. Epub 2013 Feb 23.

3.

Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor α expression in muscle tissue of patients with polymyositis or dermatomyositis.

Zong M, Loell I, Lindroos E, Nader GA, Alexanderson H, Hallengren CS, Borg K, Arnardottir S, McInnes IB, Lundberg IE.

Ann Rheum Dis. 2012 Jun;71(6):1055-63. doi: 10.1136/annrheumdis-2011-200495. Epub 2012 Jan 20.

PMID:
22267334
4.

A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.

Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, Elvin K, Crow MK, Nennesmo I, Lundberg IE.

Ann Rheum Dis. 2008 Dec;67(12):1670-7. doi: 10.1136/ard.2007.077974. Epub 2008 Feb 13.

PMID:
18272672
5.
6.

Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.

Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, Takagi K, Ichida H, Katsumata Y, Ota Y, Kawasumi H, Yamanaka H.

Rheumatology (Oxford). 2014 Dec;53(12):2196-203. doi: 10.1093/rheumatology/keu258. Epub 2014 Jun 26.

PMID:
24970922
7.

Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.

Peng QL, Zhang YL, Shu XM, Yang HB, Zhang L, Chen F, Lu X, Wang GC.

J Rheumatol. 2015 Jun;42(6):979-87. doi: 10.3899/jrheum.141307. Epub 2015 Apr 15.

PMID:
25877505
8.

Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies.

Notarnicola A, Lapadula G, Natuzzi D, Lundberg IE, Iannone F.

Scand J Rheumatol. 2015 May;44(3):224-8. doi: 10.3109/03009742.2014.956141. Epub 2014 Nov 7.

PMID:
25379698
9.

Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis.

Pandya JM, Loell I, Hossain MS, Zong M, Alexanderson H, Raghavan S, Lundberg IE, Malmström V.

Arthritis Res Ther. 2016 Apr 1;18:80. doi: 10.1186/s13075-016-0974-5.

10.

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.

Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B; Lupus Interferon Skin Activity (LISA) Study Investigators.

Ann Rheum Dis. 2011 Nov;70(11):1905-13. doi: 10.1136/ard.2010.144485. Epub 2011 Jul 27.

PMID:
21798883
11.

Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme-B genes and the protein TIA-1 in muscle biopsies of myositis.

Cherin P, Herson S, Crevon MC, Hauw JJ, Cervera P, Galanaud P, Emilie D.

J Rheumatol. 1996 Jul;23(7):1135-42.

PMID:
8823683
12.

Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response.

Gabay C, Gay-Croisier F, Roux-Lombard P, Meyer O, Maineti C, Guerne PA, Vischer T, Dayer JM.

Arthritis Rheum. 1994 Dec;37(12):1744-51.

PMID:
7986220
13.

Dermatomyositis and polymyositis: new treatment targets on the horizon.

Hak AE, de Paepe B, de Bleecker JL, Tak PP, de Visser M.

Neth J Med. 2011 Oct;69(10):410-21. Review.

14.

Interleukin-1 and tumor necrosis factor α blockade treatment of experimental polymyositis in mice.

Sugihara T, Okiyama N, Watanabe N, Miyasaka N, Kohsaka H.

Arthritis Rheum. 2012 Aug;64(8):2655-62. doi: 10.1002/art.34465.

15.

Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations.

Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, van Engelen BG.

Eur Neurol. 2003;50(1):10-5.

PMID:
12824706
16.

T-lymphocyte immunophenotyping in polymyositis and dermatomyositis.

Iannone F, Cauli A, Yanni G, Kingsley GH, Isenberg DA, Corrigall V, Panayi GS.

Br J Rheumatol. 1996 Sep;35(9):839-45.

PMID:
8810666
17.

Increased IL-15 production of muscle cells in polymyositis and dermatomyositis.

Sugiura T, Harigai M, Kawaguchi Y, Takagi K, Fukasawa C, Ohsako-Higami S, Ohta S, Tanaka M, Hara M, Kamatani N.

Int Immunol. 2002 Aug;14(8):917-24.

PMID:
12147628
18.

Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.

Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC; RIM Study Group, Oddis CV.

Arthritis Rheumatol. 2014 Mar;66(3):740-9. doi: 10.1002/art.38270.

19.

Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis.

Kurasawa K, Nawata Y, Takabayashi K, Kumano K, Kita Y, Takiguchi Y, Kuriyama T, Sueishi M, Saito Y, Iwamoto I.

Clin Exp Immunol. 2002 Sep;129(3):541-8.

20.

Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis.

Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, Beggs AH, Amato AA, Greenberg SA.

Arthritis Rheum. 2007 Nov;56(11):3784-92.

Supplemental Content

Support Center